Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart L Silverman

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
The New England Journal of Medicine|September 10, 2010
Bisphosphonates and atypical femoral fracturesStuart L Silverman, Susan M Ott, Richard M Dell
Current Medical Research and Opinion|May 20, 2006
An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US studyThomas W Weiss, Deborah T Gold, Stuart L Silverman, et al.
Lupus Science & Medicine|February 13, 2016
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation productsDaniel J Wallace, Stuart L Silverman, John Conklin, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|March 30, 2010
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapyMarc C Hochberg, Stuart L Silverman, Charles E Barr, et al.
The Journal of Rheumatology|July 15, 2003
The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal womenAlan K Oglesby, Michael E Minshall, Wei Shen, et al.
The Journal of Rheumatology|January 12, 2007
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) studyStuart L Silverman, Wei Shen, Michael E Minshall, et al.
JBMR Plus|December 12, 2024
Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United StatesJean-Yves Reginster, Stuart L Silverman, Majed Alokail, et al.
Arthritis Care & Research|August 29, 2013
Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safetyKeaton Nasser, Alan J Kivitz, Michael J Maricic, et al.
The Annals of Pharmacotherapy|March 26, 2009
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronateWilliam A Blumentals, Steven T Harris, Raymond E Cole, et al.
The Journal of Rheumatology|December 7, 2005
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosisStuart L Silverman, Veronica K Piziak, Peiqi Chen, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
The New England Journal of Medicine|September 10, 2010
Bisphosphonates and atypical femoral fracturesStuart L Silverman, Susan M Ott, Richard M Dell
Current Medical Research and Opinion|May 20, 2006
An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US studyThomas W Weiss, Deborah T Gold, Stuart L Silverman, et al.
Lupus Science & Medicine|February 13, 2016
Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation productsDaniel J Wallace, Stuart L Silverman, John Conklin, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|March 30, 2010
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapyMarc C Hochberg, Stuart L Silverman, Charles E Barr, et al.
The Journal of Rheumatology|July 15, 2003
The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal womenAlan K Oglesby, Michael E Minshall, Wei Shen, et al.
The Journal of Rheumatology|January 12, 2007
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) studyStuart L Silverman, Wei Shen, Michael E Minshall, et al.
JBMR Plus|December 12, 2024
Cost-effectiveness of radiofrequency echographic multi-spectrometry for the diagnosis of osteoporosis in the United StatesJean-Yves Reginster, Stuart L Silverman, Majed Alokail, et al.
Arthritis Care & Research|August 29, 2013
Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safetyKeaton Nasser, Alan J Kivitz, Michael J Maricic, et al.
The Annals of Pharmacotherapy|March 26, 2009
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronateWilliam A Blumentals, Steven T Harris, Raymond E Cole, et al.
The Journal of Rheumatology|December 7, 2005
Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosisStuart L Silverman, Veronica K Piziak, Peiqi Chen, et al.
Pageof 9